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Background
Mother-to-child transmission (MTCT) of HIV-1 is one of
the major issues of the pandemic. Characterization of HIV-
specific immunity during pregnancy, especially cytotoxic T
lymphocytes (CTL), will lead to a better understanding of
HIV pathogenesis and facilitate design of optimal strategies
to prevent MTCT. Our objective is to define the influence of
initiation and progression of pregnancy on the antigenic
specificity and breadth of antigenic recognition by HIV-spe-
cific CTL.
Materials and methods
Study subjects were women infected with B or non-B HIV-
1 subtypes who underwent successive pregnancies (n=11)
or wanted to become pregnant (n=4). Median age at study
entry was 27.8 years and median CD4 count was 490 cells/
mm3. All subjects were treated with combinations of
antiretroviral agents for maternal health and to prevent
MTCT. Antigenic specificity of CTL was evaluated on seri-
ally-obtained (1st, 2nd, 3d trimesters) CD4-depleted sam-
ples of peripheral blood mononuclear cells using IFN-γ
enzyme-linked immunospot assay (ELISpot). Screening
was performed with synthetic peptide matrices (20 amino
acids with 10 residue overlap) corresponding to Gag
sequences from HIV-1 clades A, B, C and D. Breadth of anti-
genic recognition was defined as the number of peptide
pools showing positive CTL reactivity.
Results
Significant variations were observed in the magnitude of
HIV-1 Gag-specific CTL responses, which ranged between
15 and 1,350 spot-forming units (SFU)/100,000 cells. Var-
iations in the breadth of antigenic recognition were also
observed, with 2-11 peptide pools generating CTL reactiv-
ity. These differences were evidenced before and after initi-
ation of pregnancy, as well as between trimesters of
gestation, and were seen in all patients irrespective of the
clade of the infecting HIV-1 variant (B, D, or CRF02_AG),
the number of antiretroviral agents used (n=2-6), and the
control of HIV-1 viral load. In all cases, CTL were targeted
to Gag regions that contained known CTL epitopes.
Conclusions
These results indicate that pregnant HIV-infected women
generate robust HIV-specific CTL responses that are capable
of simultaneously targeting multiple antigenic determi-
nants, inconsistent with a broad dysfunction of cell-medi-
ated immunity in pregnancy. These CTL responses
exhibited longitudinal variations in terms of antigenic spe-
cificity and breadth of antigenic recognition, variations that
could be explained by sequential waves of expansion and
contraction of CTL clones of mixed antigenic specificity
and/or continuing viral escape from CTL responses. These
results provide a novel understanding of the dynamics of
HIV-specific CTL responses during pregnancy and may help
to promote maternal immunization as a strategy to prevent
MTCT of HIV-1.
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